Phase 3 Trial to Assess the Safety and Efficacy of Natroba for the Treatment of Scabies

PHASE3CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

May 10, 2017

Primary Completion Date

August 3, 2018

Study Completion Date

August 3, 2018

Conditions
Scabies
Interventions
DRUG

spinosad topical suspension, 0.9%

Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

OTHER

Placebo

Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.

Trial Locations (7)

18201

DermDox Centers for Dermatology, Hazleton

19103

Paddington Testing Company, Philadelphia

34744

The Chappel Group Research, Kissimmee

77055

West Houston Clinical Research Service, Houston

78503

Discovery Clinical Trials, McAllen

90806

Long Beach Clinical Trial Services, Long Beach

92804

Saint Joseph's Clinical Research, Anaheim

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Concentrics Research

OTHER

lead

ParaPRO LLC

INDUSTRY